Table 5.
Adjusted comparisons of hospitalisations and re-admissions across treatment arms.
| Entire study |
Actionable patients |
|||||||
|---|---|---|---|---|---|---|---|---|
| Control N = 529a | PGx-guided N = 547a | OR (96% CI)b | p-valueb | Control N = 126a | PGx-guided N = 136a | OR (96% CI)b | p-valueb | |
| Hospitalisation | 187 (35.35%) | 110 (20.11%) | 0.46 (0.34, 0.61) | <0.001 | 30 (23.81%) | 22 (16.18%) | 0.60 (0.32, 1.11) | 0.11 |
| Age | 49 (40, 58) | 49 (39, 58) | 0.98 (0.97, 1.00) | 0.004 | 51 (44, 58) | 50 (39, 58) | 0.98 (0.96, 1.01) | 0.2 |
| Co-medications | 3.00 (2.00, 6.00) | 3.00 (2.00, 5.00) | 1.02 (0.97, 1.08) | 0.4 | 3.00 (1.00, 5.00) | 3.00 (2.00, 5.00) | 1.06 (0.95, 1.18) | 0.3 |
| Baseline QoL | 0.60 (0.40, 0.70) | 0.59 (0.40, 0.70) | 0.23 (0.10, 0.55) | 0.6 | 0.50 (0.40, 0.70) | 0.52 (0.40, 0.70) | ||
a
Median (IQR); n (%).
b
Logistic regression of hospitalisation on treatment arm, age, concomitant medications, diagnosis and baseline QoL (entire study) or treatment arm, age and concomitant medications (actionable patients).